

Cite this: *RSC Chem. Biol.*, 2022,
3, 69

Synthesis and preliminary evaluation of octreotate conjugates of bioactive synthetic amatoxins for targeting somatostatin receptor (sstr2) expressing cells†

Alla Pryyma,^a Kaveh Matinkhoo,^a Yong Jia Bu,^a Helen Merkens,^b
Zhengxing Zhang,^b Francois Bénard^b and David M. Perrin^b*^a

Targeted cancer therapy represents a paradigm-shifting approach that aims to deliver a toxic payload selectively to target-expressing cells thereby sparing normal tissues the off-target effects associated with traditional chemotherapeutics. Since most targeted constructs rely on standard microtubule inhibitors or DNA-reactive molecules as payloads, new toxins that inhibit other intracellular targets are needed to realize the full potential of targeted therapy. Among these new payloads, α -amanitin has gained attraction as a payload in targeted therapy. Here, we conjugate two synthetic amanitins at different sites to demonstrate their utility as payloads in peptide drug conjugates (PDCs). As an exemplary targeting agent, we chose octreotate, a well-studied somatostatin receptor (sstr2) peptide agonist for the conjugation to synthetic amatoxins via three tailor-built linkers. The linker chemistry permitted the evaluation of one non-cleavable and two cleavable self-immolative conjugates. The immolating linkers were chosen to take advantage of either the reducing potential of the intracellular environment or the high levels of lysosomal proteases in tumor cells to trigger toxin release. Cell-based assays on target-positive Ar42J cells revealed target-specific reduction in viability with up to 1000-fold enhancement in bioactivity compared to the untargeted amatoxins. Altogether, this preliminary study enabled the development of a highly modular synthetic platform for the construction of amanitin-based conjugates that can be readily extended to various targeting moieties.

Received 22nd February 2021,
Accepted 27th September 2021

DOI: 10.1039/d1cb00036e

rsc.li/rsc-chembio

Introduction

Cancer treatment with standard chemotherapeutics is limited by severe systemic toxicity owing to poor selectivity for neoplastic tissue.¹ Targeting agents designed to bind specific tumor markers expressed on cancer cell surfaces can improve the therapeutic index of chemotherapeutics^{2,3} and harness the potential of toxins not typically used in therapy.^{4,5} Thus, bioconjugates comprising a targeting moiety linked to a toxin display up to 1000-fold lower IC₅₀ values against target-expressing cells compared to the IC₅₀ values of unconjugated cytotoxins, thus enabling deadly compounds to be used at tolerable doses.⁶ Generally, antibodies are employed to selectively deliver agents to malignant cells.^{1,6–9} To wit, nine antibody drug conjugates (ADCs) have received FDA approval (five in the past two

years alone) while over 80 ADCs are undergoing clinical trials.^{7,10,11} This recent clinical success is accompanied by intense research on aptamer- and peptide-targeted drugs and suggests that targeted conjugates of all kinds are poised for success.^{12–14}

Whereas the majority of targeted therapeutics in clinical development exploit microtubule inhibitors (*e.g.* auristatins, maytansinoids, vincristine)^{3,15–18} or DNA-reactive cytotoxins (*e.g.* camptothecin, calicheamicin, doxorubicin)^{19–21} as standard payloads, instances of induced resistance are documented.^{22,23} This highlights the need for new payloads targeting alternative intracellular targets. One such payload is α -amanitin (1), a potent RNA polymerase II (pol II) inhibitor isolated from the fatal “death-cap” mushroom, *Amanita phalloides* (Fig. 1).^{24,25} Because RNA pol II is required for both cellular growth and homeostasis, α -amanitin, a potent cytotoxin, kills both actively dividing and quiescent cells, presenting a unique advantage over other payloads that act preferentially on rapidly growing cells. Additional favorable properties of amanitin include water solubility and plasticity of conjugation at multiple sites on the toxin.

Albeit one of the deadliest known toxins, in 1981, α -amanitin was successfully used as an ADC payload²⁶ and subsequently

^a Department of Chemistry, University of British Columbia, 2036 Main Mall,
Vancouver, BC, V6T 1Z1, Canada. E-mail: dperrin@chem.ubc.ca^b Department of Molecular Oncology, BC Cancer, Vancouver, BC, V5Z 1L3, Canada

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1cb00036e






Fig. 1 Chemical structure of α/β -amanitin with commonly used conjugation sites highlighted with green.

validated in more potent amanitin-ADCs that exhibit negligible hepatotoxicity *in vivo*.^{27–32} By contrast, peptide drug conjugates (PDCs) of amanitin have been limited to integrin-targeting^{31,33} and pH-responsive “acidic” peptides.^{34,35} Irrespective of linker design (*i.e.* non-cleavable or cleavable), these particular compositions would appear to have questionable utility owing to a general lack of potency and/or minimal selectivity for target tissue.^{31,33} Since this work was submitted, Gallo *et al.* described a novel, highly efficacious class of amanitin drug constructs, that incorporates a small molecule peptidomimetic for targeting prostate specific membrane antigen and an immunoglobulin Fc domain for improved pharmacokinetics.³⁶

Peptides are attractive as they show excellent tumor specificity while overcoming known disadvantages of antibodies *e.g.* high manufacturing cost, low tissue penetration, aggregation, and immunogenicity.³⁷ In light of recent synthetic breakthroughs for accessing bioactive amatoxins by us^{33,38–40} and others,^{33,38–40} we were compelled to use this practical knowledge to expand the repertoire of amanitin-based cancer therapeutics with new, synthetic amanitins.

Towards these ends, we report on the design of a modular and user-friendly approach to enable bio-orthogonal conjugation of synthetic amanitins to three different linkers that are elaborated to three potent peptide-amanitin conjugates (Fig. 2) that differ by their mode of toxin release, as defined by the linker. Octreotate (TATE- N_3 , 2) was chosen as it is a circulation-stable octapeptide somatostatin analog that agonizes somatostatin receptors ($K_d \sim 0.4$ nM for sstr2).^{41,42} Targeting sstr2 has been successfully exploited for drug delivery,^{43–45} cancer imaging,^{46,47} and radiotherapy^{42,47} owing to the high levels of sstr2 expression on neuroendocrine tumors (*e.g.* carcinoids, pancreatic islet cell tumors, thyroid carcinomas, and small lung cancer to name a few). While this is the first report of an octreotate-amanitin conjugate, herein, octreotate serves as an exemplar to highlight the potential for developing peptide-amanitin conjugates in targeted applications.

Cell proliferation studies revealed that the conjugates are cytotoxic (or at least cytostatic) in the nanomolar range. This observation is further supported by kinetics of cell death, fluorescence microscopy studies, and blocking controls. To the best of our knowledge, this work is the first example of conjugating amanitin to a high-affinity peptide that targets a G-coupled protein receptor of significant interest to

cancer therapy and which improves the apparent selectivity of the toxin for the intended target over the unconjugated toxin.

Results and discussion

In designing peptide-amanitin conjugates, we recognize that the majority of amanitin-based ADCs and PDCs have relied nearly exclusively on naturally-sourced α - and β -amanitin (Fig. 1). Loci for conjugation on the toxin include the δ -hydroxyl of dihydroxyisoleucine,^{27,48} the asparagine side chain,⁴⁹ and the 6'-hydroxyl of the tryptathionine staple.^{28,29,31,50,51} In some cases, these have been linked either to reducible or proteolyzable linkers, or to linkers assumed to be non-cleavable for which the metabolic fate is usually unknown.

A key advance in the development of any cytotoxic payload is access to synthetic toxins and analogs thereof. In 2018, we disclosed the first total synthesis of this venerated toxin,³⁸ which was followed by two others.^{39,40} Whereas *a priori* these routes now provide synthetic access, challenges remain regarding efficiency and scalability, particularly in terms of accessing a 6'-hydroxytryptathionine staple and the (*R*)-sulfoxide (although both the thioether and sulfone are equally cytotoxic). To expand the potential for new amanitin derivatives, we recently reported the synthesis of an unnatural 5'-hydroxy-6'-deoxy-amanitin (3) that is equipotent to α -amanitin (along with the corresponding (*R*)-sulfoxide, and the sulfone).⁵² With this more synthetically accessible toxin in hand, here we report on conjugates that would exploit the 5'-hydroxy-6'-deoxy-amanitin 3 (Fig. 2B). We further expand this study on octreotate conjugates to include conjugation to *N*-propargyl-dideoxy-amanitin 4 (Fig. 2B),³³ an alternative, equally synthetically accessible derivative that lacks the 6'-hydroxyindole yet shows near-native toxicity (IC₅₀ on CHO cells 1–2 μ M compared to 0.3–0.7 μ M for α -amanitin) and is equipped with an alkyne conjugation handle for copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC).

In considering a non-cleavable linker, we note that PEGylation of various toxins has been shown to enhance pharmacokinetic properties⁵³ and aid in overcoming hydrophobicity.⁵⁴ Whereas PEG linkers were used in the context of RGD-amanitin,³¹ because they are assumed to be non-cleavable, they would likely degrade slowly inside cells, which is consistent with decreased overall potency. Nevertheless, several antecedent studies showed that non-cleavable linkers to amanitin still provide highly cytotoxic conjugates (see Discussion).

More promising therefore are linkers that liberate the toxin from the targeting vector once inside cells. A review of the vast literature on circulation-stable linkers reveals two well-established classes of cleavable linkers that are advancing to clinical studies. These include: (i) disulfide-linked, first introduced in 2006,^{55–57} which decompose upon reductive cleavage in the intracellular reducing environment *via* cyclization either to a thiocarbonate^{58–60} or an episulfide with expulsion of CO₂^{61,62} and concomitant release of the active drug (Fig. 2C),^{55,57,63,64} and (ii) protease cleavable (*e.g.* Cathepsin B) linkers, which are degraded by lysosomal proteases that are overexpressed in cancer cells.^{65,66}






Fig. 2 (A) Chemical structures of sstr2 targeting agent octreotate (TATE- N_3 , **2**); (B) synthetic bioactive amatoxins **3** and **4**; (C) three bioconjugates **5–7** synthesized in this study. Highlighted in blue and red are conjugation sites; (a) and (b) show two proposed pathways for self-immolative drug release of bio-reducible linker conjugate **6**.

The use of *N*-propargyl-amanitin **4** enables production of both cleavable and non-cleavable constructs. Hence, we designed a PEG-based non-cleavable conjugate **5** and a disulfide-containing bio-reducible, self-immolative conjugate **6** (Fig. 2C). In the context of grafting to the tryptathionine staple, we noted antecedent reports of amanitin–RGD peptide conjugates linked to the 6'-hydroxyl group in amanitin.³¹ Following our recent report on the more synthetically accessible 5'-hydroxytryptathionine-stapled amanitin,⁵² we took advantage of the nucleophilicity of the 5'-hydroxyl group for grafting linkers to the 5'-hydroxytryptathionine as well. Towards this end, we appreciated the recent success of valine–citrulline (Val–Cit) Cathepsin B cleavable linkers in FDA approved ADCs.^{65,67} A favorable feature of Val–Cit linkers is the presence of a

self-immolative *p*-aminobenzyloxycarbonyl (PABC) spacer which decomposes upon deacylation, prompting a spontaneous release of the toxin in its free unmodified form (Fig. 2C). Hence, we designed bioconjugate **7** employing a Val–Cit–PABC linker conjugated to 5'-hydroxy-6'-deoxy-amanitin **3** (Fig. 2C).

Considerations for designing modular linkers for bioorthogonal toxin conjugation

In pursuit of linkers for amatoxins **3** and **4**, we sought a degree of modularity for bioorthogonal conjugation while providing optionality for state-of-the-art immolation. The linkers designed for conjugation to amatoxin **4** were equipped with two orthogonally protected conjugation handles that take advantage of CuAAC conjugation, namely an azide and a TES-protected alkyne, that



Scheme 1 Synthetic approach towards a modular assembly of conjugates **5**, **6**, and **7** employing linkers with suitable orthogonal protecting groups; (A) PEG-linked and disulfide-containing bio-reducible conjugate **5** and **6** of amatoxin **4**; (B) Cathepsin B cleavable self-immolative conjugate of amatoxin **3**.



follow elegant reports by Aucagne^{68,69} and others⁷⁰ (Scheme 1). For conjugation, we favored the CuAAC reaction owing to its fast kinetics, bio-orthogonality, and compatibility with a broad range of solvents.^{71–74}

To assemble the conjugates, **4** was first reacted with the azide of the linker *via* CuAAC (Scheme 1A). Removal of the TES group was then carried out to reveal the alkyne for use in the second CuAAC reaction with the azide of targeting agent **2**, yielding two peptide–amanitins **5** and **6** (Scheme 1A). In a similar vein, we created a second class of alkyne-based linker with an activated *p*-nitrophenyl carbonate for selective acylation of the 5'-hydroxytryptathionine of **3** and CuAAC conjugation to azide containing peptide **2** to provide conjugate **7** (Scheme 1B).

Linker synthesis

The non-cleavable PEG-linker **10** was constructed by reacting the freshly prepared TES-protected propargyl amine **8** with a commercially available azido-PEG₈-NHS ester **9** (Fig. 3A) in 73% yield. The bio-reducible linker **16** was designed with a disulfide bridge in proximity to the carbamate ester (Fig. 3B). We opted for a carbamate linkage instead of a carbonate one, due to the known sensitivity of carbonates to hydrolysis,^{55,64} which could potentially result in handling difficulties and premature release of the toxin as well as decomposition during purification, as we observed (data not shown). Synthesis of **16** was carried out as shown in Fig. 3B.

To assemble the carbamate ester, azidoethylamine **11** was first reacted with *p*-nitrophenyl chloroformate to give **12**

followed by reaction with the alcohol of the mixed disulfide-bridged 2-(pyridine-2-yl-disulfanyl) ethanol **13** to produce **14**. The mixed disulfide-bridged **14** was exchanged with mercaptopropionic acid in water/DMF at pH 6 under argon to give **15** in 82% yield (Fig. 3B). Finally, the carboxylic acid of **15** was coupled to the TES-protected propargylamine **8** to afford the final linker **16** (Fig. 3B).

A Cathepsin B cleavable linker **18** was assembled by a combination of solid- and solution-phase synthesis as described previously (Fig. 3C).^{75,76} Briefly, 2-chlorotrityl chloride resin was elaborated with Cit-Val-pentynoate under Oxyma-buffered solid-phase conditions.⁷⁵ Resin cleavage followed by direct coupling to *p*-aminobenzyl alcohol produced **17**, which was activated with bis-*p*-nitrophenyl carbonate to yield target linker **18** (Fig. 3B).

Assembly of TATE-amanitin bioconjugates 5–7

This convergent synthesis enabled bioconjugates to be efficiently and rapidly constructed from propargyl-amanitin **4** in three steps (Scheme 2A) to give **5** and **6** in good yields. First, the azides of linkers **10** and **16** were coupled to **4** *via* CuAAC to yield **19** and **20**, respectively (Scheme 2A). We found that the addition of tris(benzyltriazolylmethyl)amine (TBTA) as a ligand for Cu(II) greatly increased the reaction rate and allowed for the reaction to proceed to completion in one hour and at a low concentration of amatoxin **4** (0.5 mM). The alkyne functionality was then unmasked *via* facile and clean TES removal with excess KHF₂ in dimethyl sulfoxide (DMSO) at 60 °C. Excess KHF₂ was readily





Fig. 3 Synthesis of bifunctional linkers **10**, **16** and **18**: (A) PEG-based linker containing TES protected alkyne and azide handles; (B) linker **16** containing a bio-reducible disulfide, a TES protected alkyne; (C) Cathepsin B cleavable linker **18** functionalized with an alkyne and a *p*-nitrophenyl carbonate ester; py – pyridyl.





Scheme 2 (A) Final steps of the synthesis of non-cleavable and disulfide containing bioconjugates **5** and **6** through CuAAC reaction; (B) final steps of the synthesis of Cathepsin B cleavable bioconjugate **7**; ^astarting material (**3**) was partially recovered.

removed by a simple C18 Sep-Pak work-up. The free alkyne was then coupled to TATE-N₃ **2** to afford the final conjugates TATE-PEG-Ama **5** and TATE-SS-Ama **6** (Scheme 2A).

Conjugate **7** was efficiently assembled in two steps from amanitin **3** and linker **18** (Scheme 2B). The 5'-hydroxyl of amanitin **3** was reacted with Val-Cit-PABC-PNP linker **18** in the presence of DMAP and pyridine as a solvent to afford compound **21**. This transformation was accompanied by a change to the UV-Vis absorption spectrum resulting from the acylation of the 5'-hydroxytryptathionine chromophore. CuAAC reaction of the alkyne **21** with TATE-N₃ **2** yielded final conjugate **7** (Scheme 2B).

Biological evaluation

With bioconjugates **5–7** in hand, we evaluated their cytotoxicity by assaying cell viability on an sstr2-positive rat pancreatic cancer Ar42J cells, using free amatoxins as controls. The MTS cell viability assay showed that all three PDCs were effective at reducing the viability of Ar42J cells in the low nM range, providing calculated EC₅₀ values of 4.2, and 2.3 nM for conjugates **6** and **7**, respectively (Fig. 4); these displayed up to 1000-fold enhancement in apparent cytotoxicity compared to free amatoxins **3** and **4**, both of which gave calculated EC₅₀ values of ~2 μM. This points to successful targeting and intracellular accumulation of toxin inside cells through an sstr2-mediated uptake inside the cells.

Further evidence supporting target-mediated uptake is the micromolar toxicity of bioconjugates to the sstr2-negative CHO cell line that is otherwise sensitive to non-targeted amanitin (see Fig. S1, ESI[†]). In comparison to α-amanitin and synthetic amatoxins **3** and **4**, bioconjugates **5–7** are 7- to 14-fold less toxic to CHO cells (control cell line), likely owing to impaired uptake of octreotate-amanitin conjugates that must enter *via* diffusion mediated processes or other non-specific import mechanisms that are currently unknown. In addition, a blocking study was




Fig. 4 Cytotoxicity of amanitin-based conjugates **5**, **6** and **7** to Ar42J cells expressing sstr2 in cell proliferation MTS assay; cells were incubated with TATE-PEG-Ama **5**, TATE-SS-Ama **6**, TATE-VCit-Ama **7**, TATE-N₃ **2** and amatoxins **1**, **3** and **4** for 72 h at 37 °C (*n* = 3), EC₅₀ (effective concentration giving half-maximal response), data represented as mean value ± S.D., n/d – not determined.

run in the presence of free TATE-N₃ **2**, which led to the expected reduction in apparent toxicity (see Fig. S2, ESI[†]).

When comparing the two cleavable bioconjugates **6** and **7**, it is important to consider the identity of the active toxin liberated inside the cell following the targeted delivery. Based on considerable precedent with these types of linkers, the self-immolation of bioconjugate **7** is expected to release the unmodified toxin **3**, whereas, degradation of bioconjugate **6** liberates amanitin **22** with a pendant ammonium-ethyl (Fig. 5) triazole, which might be expected to reduce toxicity, particularly if the ammonium cation hinders lysosomal escape.

Indeed, following a deliberate degradation of disulfide-containing bioconjugate to obtain **22**, we found **22** to be about 10-fold less toxic to CHO cells compared to **4** (EC₅₀ ~ 5 μM, see Fig. S1, ESI[†]). The exact reason for apparent diminished toxicity is difficult to establish at this juncture: **22** may have a





Fig. 5 Structure of the toxin liberated inside of the targeted cells as a result of the disulfide reduction and self-immolation of bioconjugate TATE-SS-Ama **6**.

diminished affinity for RNA pol II or it may penetrate cells relatively inefficiently due to the presence of the charged ammonium-ethyl residue, or both.

Interestingly, even though conjugates **6** and **7** immolate *via* two different mechanisms, both elicited a similar response (Fig. 4). Reduction in cell viability in the case of **6** and **7** will be governed by complex effects: (i) the affinity of the targeting agent for its receptor, (ii) the extent of toxin internalization, (iii) the inherent IC_{50} of the liberated toxin once internalized, and (iv) the effective intracellular concentration of toxin. While the confluence of these effects and the various kinetic steps that govern them makes it difficult to assess which of the above (i–iv) is limiting, these observations show that a combination of target-specific binding, active uptake, internalization, and immolation contribute to a sufficiently high concentration of toxin that results in substantial reduction in viability.

As anticipated, octreotate-amanitin conjugates linked by the immolating linkers showed greater overall toxicity than the non-cleavable PEG-linked conjugate **5**, interestingly however, **5** still showed activity. Nevertheless, the data obtained using non-cleavable PEG-linked construct **5** were not sufficiently robust to allow us to reliably calculate an EC_{50} value. This result adds to a growing body of critical knowledge on reports of amanitin-conjugates comprising linkers prepared by amide-bond formation with β -amanitin that are presumed to be non-cleavable. To wit, amanitin-conjugates linked *via* an amide bond to albumin,⁴⁹ epidermal growth factor,⁷⁷ as well as to both RGD and PEG-rhodamine³³ have all shown potent activity, despite the use of non-cleavable linkers linked to the Asp/Asn. In none of the above reports, however, did the authors establish that the amanitin toxin was liberated. In contrast, however, non-cleavable linkers grafted to the 6'-hydroxytryptathionine and linked to RGD were found to be essentially non-toxic.³¹

Notably, only partial killing of Ar42J cells was observed during the MTS assays for all three PDCs. This phenomenon is often observed in *in vitro* cell viability studies on cancer cells and has spurred numerous studies.^{78–81} It is well-known that cellular heterogeneity and cell-to-cell variability are present to some degree in any cell population and the overall behaviour of the population gleaned by the means of cell-population-

averaged techniques does not represent an individual cell.⁷⁹ Stochastic fluctuations inherent to biological systems can cause changes in gene and protein expression levels.^{80,82,83} Consequently, the levels of mRNA, proteins, metabolites, and other cellular components may result in the emergence of phenotypically distinct subpopulation and genetically identical cells to respond differently to sudden stress and become more or less sensitive to a drug, which may prove either cytotoxic or simply cytostatic.^{80,82,83} Because amanitin is known to induce cell death, we contend that the concentration-dependent depletion of *sstr2*-expressing cells in the presence of **5–7** is likely explained by cytotoxicity and not simply cytostasis.

In an effort to understand the partial reduction in cell viability, we applied FACS scanning to assess the *sstr2* levels as function of time as well as in response to Ama-SS-TATE **6**. To do this, we synthesized a TATE-PEG₂-fluorescein (**S7**) as a fluorescent reporter ligand. Ar42J cells were plated for varying lengths of time (48, 72, 96, and 120 hours). In our hands, in the absence of **6**, Ar42J cells appeared to undergo a time-dependent loss of *sstr2* resulting in a subpopulation that shows significantly lower *sstr2* expression and approaches approximately 50% of the overall population (Fig. 6). When the same cells were incubated with **6** (30 nM) for the same length of time, we observed a depletion in the *sstr2*-expressing population. Similar results were obtained when cells were treated with **6** at 60 nM (see ESI†). We should caution that this analysis proved technically difficult and additional attempts were confounded by excessive clumping of these cells in culture while FACS scans showed even more dramatic reduction in apparent *sstr2* expression (data not shown).



Fig. 6 FACS scan of Ar42J cells that were untreated (gray) show a time-dependent increase in an *sstr2*-negative population from 48–96 h. Cells treated with **6** (30 nM) show a similar effect (black), however, the *sstr2*-positive population is depleted in comparison to the *sstr2*-negative population. Similar results were also observed when cells were treated with **6** at 60 nM (see ESI†).



Although an explanation for this striking and altogether unexpected reduction in the *sstr2* expression levels over time is not readily intuited, this observation suggests that the apparent loss of Ar42J viability in the presence of **6**, as measured by MTS assays, is due to a loss of target expression in a sub-population of cells and otherwise cytotoxic action of **6** on those cells that expressed the target. Notwithstanding, this result also suggests that **6** is highly potent against those cells that are *sstr2*-positive since by 96 h, there appears to be a dramatic reduction in the number of *sstr2*-positive cells.

Fluorescence studies – receptor binding of TATE-linked conjugates

To further substantiate uptake and internalization of TATE-linker conjugates, albeit indirectly, we designed a fluorescent surrogate **23** where TATE-N₃ **2** was conjugated to rhodamine *via* the same linker chemistries used for the synthesis of **6** (Fig. 7a). Given the structural similarity between TATE-SS-rhodamine **23** and TATE-SS-Ama **6**, we expected that **23** would also bind selectively to Ar42J cells.

The synthesis was effected by coupling rhodamine-piperazine-hexynamide equipped with disulfide linker **16** to octreotate **2** (see Scheme S1, ESI[†]). We used rhodamine instead of fluorescein to red-shift the fluorescent emission. Using fluorescence microscopy, we then evaluated cell-specific binding and uptake by *sstr2*-positive cells. We first assessed the binding capability of TATE-SS-Rhod **23** to Ar42J cells; in the presence of 5 nM **23**, strong fluorescence was observed. Hence, Ar42J cells were treated with a 5 nM concentration of **23** in the presence of a 50-fold excess of **6** to block the binding of **23** (Fig. 7a and b). Using fluorescence microscopy, we observed that indeed TATE-SS-Ama **6** successfully blocked the binding of **23** (Fig. 7b). This observation further validates the targeted enrichment of toxin inside the cells.




Fig. 7 Fluorescence imaging of Ar42J cancer cells (*sstr2*-positive) using TATE-SS-Rhod **23**; (a) cells were incubated with 5 nM TATE-SS-Rhod **23** for 30 min – control; (b) blocking – cells were pre-treated with 250 nM TATE-SS-Ama **6** (30 min) followed by incubation with 5 nM TATE-SS-Rhod **23** (30 min).




Fig. 8 Cell death kinetics of bioconjugate TATE-SS-Ama **6** and α -amanitin **1** evaluated on Ar42J cells following 24 and 48 hours of incubation (MTS, $n = 3$), data reported as mean \pm S.D.; * $P < 0.01$; control experiments are cells grown under the same conditions and treated with 0.5% DMSO (vehicle) culture media.

Cell death time-course studies

Measuring cell viability as a function of time revealed a relatively rapid loss of cell viability with disulfide-linked conjugate **6** (60 nM) after only 24 hours of incubation with no further reduction thereafter (Fig. 8). In contrast, the same cells when treated with a much higher concentration (10 μ M) of free α -amanitin **1** remained fully viable after 24 hours (Fig. 8) and loss of cell viability was only observed after 48 hours. It is well-known that in the absence of organic anion transport proteins normally found on hepatocytes, α -amanitin enters cells by passive diffusion through the plasma membrane.⁸⁴ With toxicity directly correlated to plasma membrane permeability along with increased lipophilicity,⁸⁵ the comparatively larger conjugates are less active than the synthetic amanitins used for conjugation. The relatively repaired kinetics of cell death observed here along with the fact that cell death occurs at nearly 1000-fold lower concentrations suggests an increase in the rate of accumulation of amanitin in the cells treated with the bioconjugate, suggesting a receptor-mediated mechanism of cell entry. We note that these data were generated by MTS assays which may result in discrepancies compared to the data obtained by FACS scanning, which suggested that cell death may take a slightly longer time. While we do not have an immediate explanation for this discrepancy, we suggest that qualitatively these data are consistent with the notion of *sstr2*-targeting by novel octreotate-amanitin conjugates, the synthesis of which has been the focus of this work.

Conclusions

Here we report on the development of three novel somatostatin receptor-targeting PDCs of two different amatoxins and octreotate peptide. Whereas previous reports on amanitin based bioconjugates largely relied on naturally sourced α - and



β -amanitin, this work highlights the use of synthetically accessible amatoxins **3** and **4**. Moreover, this work elaborates a modular synthesis and conjugation chemistry of three linkers specifically designed to react with these analogs. The use of 5'-hydroxy-6'-deoxy-amanitin **3** as a payload for targeted therapy is demonstrated for the first time along with successful conjugation chemistry compatible with this analog.

Two cleavable conjugates, taking advantage of the reducing intracellular environment and elevated levels of Cathepsin B protease in cancerous cells, and a non-cleavable PEG-linked bioconjugate, were evaluated on somatostatin-expressing Ar42J cell line. We believe the modularity of the synthetic platform described in this work can be immediately applicable to other targeting agents equipped to undergo CuAAC reaction.

All three constructs represent the first examples of peptide-amanitin conjugates that elicit a cellular response consistent with target-specific toxin delivery in the nM-range. Nevertheless, cell viability inhibition was incomplete even though bioconjugates reduced the number of viable Ar42J cells in a concentration dependent fashion. To probe this, FACS scanning demonstrated that Ar42J cells in culture media underwent time-dependent divergence to give a second, distinct population with a significantly lower target expression. This may account for the observed response in the cell viability assay, which showed approximately 50% maximum cell lethality.

When the same conjugates were applied to cells that did not express the target (*i.e.* CHO cells), the conjugates were far less active than even amanitin itself, an observation that is consistent with lower passive uptake of a conjugate comprising two peptides. Use of a fluorescent octreotate conjugate demonstrated that binding of this fluorescent probe could be blocked with TATE-SS-Ama, which is consistent with receptor binding. Similarly, when TATE-N₃ was added, toxicity was significantly blocked.

Although we did not conclusively establish that receptor mediated endocytosis is responsible for the activity of these conjugates onsstr2-expressing cells, such is likely to be operative to account for reduction in cell viability elicited at low-to-mid nanomolar concentrations. In addition, as the MTS assay only quantifies cell viability, we cannot distinguish cytotoxicity from cytostasis. Notwithstanding, because amanitin is a known cytotoxin, we submit that the reduction in cellular viability is due to cell death.

Notably, salient points of this work include: (i) use of fully synthetic and unnatural amanitin analogs to expand access to this class of toxin, (ii) modular design of cleavable and non-cleavable linkers for concise directional conjugation, and (iii) the first report of amanitin conjugation to octreotate which is of considerable interest in cancer targeting and imaging. Finally, in view of the urgent need for anti-cancer therapeutics that inhibit non-standard intracellular targets (*i.e.* RNA pol II), the findings presented here are of mechanistic and therapeutic significance. It is anticipated that this work would expand the repertoire of octreotate-based therapeutics while providing empowering synthetic routes to consider in the design of numerous linkers of varied composition including the use of

alternative immolative functionalities, which could be conjugated to octreotate, octreotide, or to other PDCs based on amanitin or other synthetic amatoxins. This work may also inform the design of antibody drug conjugates based on similar linkers.

Author contributions

The manuscript was written by AP and DMP and synthetic work was executed by AP, KM, and YJB with the exception of the synthesis of TATE-N₃ that was effected by ZZ. FACS scanning was performed by HM in the laboratory of FB who consulted on the use of cell lines and evaluated the FACS data.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors acknowledge financial support from the Canadian Institutes for Health Research #220656 and the Canadian Cancer Society Research Initiative Grant #703374 and thank Dr Maria Ezhova for help with NMR acquisition, Dr Elena Polishchuk, and Ms Jessie Chen for help with cytotoxicity assays.

Notes and references

- 1 R. V. J. Chari, *Acc. Chem. Res.*, 2008, **41**, 98–107.
- 2 T. Ghose and S. P. Nigam, *Cancer*, 1972, **29**, 1398–1400.
- 3 B. C. Laguzza, C. L. Nichols, S. L. Briggs, G. J. Cullinan, D. A. Johnson, J. J. Starling, A. L. Baker, T. F. Bumol and J. R. F. Corvalan, *J. Med. Chem.*, 1989, **32**, 548–555.
- 4 K. C. Nicolaou and S. Rigol, *Angew. Chem., Int. Ed.*, 2019, **58**, 11206–11241.
- 5 K. Strebhardt and A. Ullrich, *Nat. Rev. Cancer*, 2008, **8**, 473–480.
- 6 R. V. J. Chari, M. L. Miller and W. C. Widdison, *Angew. Chem., Int. Ed.*, 2014, **53**, 3796–3827.
- 7 P. Khongorzul, C. J. Ling, F. U. Khan, A. U. Ihsan and J. Zhang, *Mol. Cancer Res.*, 2020, **18**, 3–19.
- 8 M. Srinivasarao, C. V. Galliford and P. S. Low, *Nat. Rev. Drug Discovery*, 2015, **14**, 203–219.
- 9 L. Ducry and B. Stump, *Bioconjugate Chem.*, 2010, **21**, 5–13.
- 10 F. Pretto and R. E. FitzGerald, *Regul. Toxicol. Pharm.*, 2021, **122**, 5.
- 11 P. L. Salomon, E. E. Reid, K. E. Archer, L. Harris, E. K. Maloney, A. J. Wilhelm, M. L. Miller, R. V. J. Chari, T. A. Keating and R. Singh, *Mol. Pharmaceutics*, 2019, **16**, 4817–4825.
- 12 R. He, B. Finan, J. P. Mayer and R. D. DiMarchi, *Molecules*, 2019, **24**, 1855.
- 13 M. Roveri, M. Bernasconi, J. C. Leroux and P. Luciani, *J. Mat. Chem. B*, 2017, **5**, 4348–4364.
- 14 Y. Gilad, M. Firer and G. Gellerman, *Biomedicines*, 2016, **4**, 24.



- 15 A. Maderna and C. A. Leverett, *Mol. Pharmaceutics*, 2015, **12**, 1798–1812.
- 16 R. V. Chari, B. A. Martell, J. L. Gross, S. B. Cook, S. A. Shah, W. A. Blättler, S. J. McKenzie and V. S. Goldmacher, *Cancer Res.*, 1992, **52**, 127–131.
- 17 G. D. L. Phillips, G. Li, D. L. Dugger, L. M. Crocker, K. L. Parsons, E. Mai, W. A. Blättler, J. M. Lambert, R. V. Chari and R. J. Lutz, *Cancer Res.*, 2008, **68**, 9280–9290.
- 18 M. Barok, H. Joensuu and J. Isola, *Breast Cancer Res.*, 2014, **16**, 1–12.
- 19 P. J. Burke, P. D. Senter, D. W. Meyer, J. B. Miyamoto, M. Anderson, B. E. Toki, G. Manikumar, M. C. Wani, D. J. Kroll and S. C. Jeffrey, *Bioconjugate Chem.*, 2009, **20**, 1242–1250.
- 20 P. Trail, D. Willner, S. Lasch, A. Henderson, S. Hofstead, A. Casazza, R. Firestone, I. Hellstrom and K. Hellstrom, *Science*, 1993, **261**, 212–215.
- 21 A. D. Ricart, *Clin. Cancer Res.*, 2011, **17**, 6417–6427.
- 22 S. García-Alonso, A. Ocaña and A. Pandiella, *Cancer Res.*, 2018, **78**, 2159–2165.
- 23 D. M. Collins, B. Bossenmaier, G. Kollmorgen and G. Niederfellner, *Cancer*, 2019, **11**, 394.
- 24 T. J. Lindell, F. Weinberg, P. W. Morris, R. G. Roeder and W. J. Rutter, *Science*, 1970, **170**, 447–449.
- 25 T. Wieland and H. Faulstich, *Experientia*, 1991, **47**, 1186–1193.
- 26 M. T. B. Davis and J. F. Preston, *Science*, 1981, **213**, 1385–1388.
- 27 G. Moldenhauer, A. V. Salnikov, S. Luttgau, I. Herr, J. Anderl and H. Faulstich, *J. Natl. Cancer Inst.*, 2012, **104**, 622–634.
- 28 S. Park, S. Y. Kim, J. Cho, D. Jung, D. Seo, J. Lee, S. Lee, S. Yun, H. Lee, O. Park, B. Seo, S. Kim, M. Seol, S. H. Woo and T. K. Park, *Bioconjugate Chem.*, 2019, **30**, 1969–1978.
- 29 S. Park, S. Y. Kim, J. Cho, D. Jung, D. Seo, J. Lee, S. Lee, S. Yun, H. Lee, O. Park, B. Seo, S. H. Woo and T. K. Park, *Bioconjugate Chem.*, 2019, **30**, 1957–1968.
- 30 T. Hechler, M. Kulke, C. Mueller, A. Pahl and J. Anderl, *Cancer Res.*, 2014, **74**, 1.
- 31 L. Boderio, P. L. Rivas, B. Korsak, T. Hechler, A. Pahl, C. Muller, D. Arosio, L. Pignataro, C. Gennari and U. Piarulli, *Beilstein J. Org. Chem.*, 2018, **14**, 407–415.
- 32 V. Figueroa-Vazquez, J. Ko, C. Breunig, A. Baumann, N. Giesen, A. Palfi, C. Muller, C. Lutz, T. Hechler, M. Kulke, C. Muller-Tidow, A. Kramer, H. Goldschmidt, A. Pahl and M. S. Raab, *Mol. Cancer Ther.*, 2021, **20**, 367–378.
- 33 L. Zhao, J. P. May, A. Blanc, D. J. Dietrich, A. Loonchanta, K. Matinkhoo, A. Pryma and D. M. Perrin, *ChemBioChem*, 2015, **16**, 1420–1425.
- 34 A. Moshnikova, V. Moshnikova, O. A. Andreev and Y. K. Reshetnyak, *Biochemistry*, 2013, **52**, 1171–1178.
- 35 D. Weerakkody, A. Moshnikova, N. S. El-Sayed, R.-C. Adochite, G. Slaybaugh, J. Golijanin, R. K. Tiwari, O. A. Andreev, K. Parang and Y. K. Reshetnyak, *Sci. Rep.*, 2016, **6**, 1–13.
- 36 F. Gallo, B. Korsak, C. Muller, T. Hechler, D. Yanakieva, O. Avrutina, H. Kolmar and A. Pahl, *J. Med. Chem.*, 2021, **64**, 4117–4129.
- 37 F. Araste, K. Abnous, M. Hashemi, S. M. Taghdisi, M. Ramezani and M. Alibolandi, *J. Controlled Release*, 2018, **292**, 141–162.
- 38 K. Matinkhoo, A. Pryma, M. Todorovic, B. O. Patrick and D. M. Perrin, *J. Am. Chem. Soc.*, 2018, **140**, 6513–6517.
- 39 M. A. J. Siegert, C. H. Knittel and R. D. Sussmuth, *Angew. Chem., Int. Ed.*, 2020, **59**, 5500–5504.
- 40 C. Lutz, W. Simon, S. Werner-Simon, A. Pahl and C. Muller, *Angew. Chem., Int. Ed.*, 2020, **59**, 11390–11393.
- 41 Q. Wang, K. Graham, T. Schauer, T. Fietz, A. Mohammed, X. X. Liu, J. Hoffend, U. Haberkorn, M. Eisenhut and W. Mier, *Nucl. Med. Biol.*, 2004, **31**, 21–30.
- 42 P. A. Whetstone, H. Akizawa and C. F. Meares, *Bioconjugate Chem.*, 2004, **15**, 647–657.
- 43 B. Redko, E. Ragozin, B. Andreii, T. Helena, A. Amnon, S. Z. Talia, O.-H. Mor, K. Genady and G. Gary, *Pept. Sci.*, 2015, **104**, 743–752.
- 44 J. B. Engel, A. V. Schally, J. Dietl, L. Rieger and A. Honig, *Mol. Pharmaceutics*, 2007, **4**, 652–658.
- 45 L. C. Sun, L. V. Mackey, J. Luo, J. A. Fuselier and D. H. Coy, *Clin. Med. Oncol.*, 2008, **2**, 491–499.
- 46 Y. Menda and D. Kahn, *Semin. Nucl. Med.*, 2002, **32**, 92–96.
- 47 M. de Jong, W. A. Breeman, D. J. Kwekkeboom, R. Valkema and E. P. Krenning, *Acc. Chem. Res.*, 2009, **42**, 873–880.
- 48 A. Pahl, C. Lutz and T. Hechler, *Drug Discovery Today Technol.*, 2018, **30**, 85–89.
- 49 G. Barbantibrodano and L. Fiume, *Nature*, 1973, **243**, 281–283.
- 50 K. W. Swiderska, A. Szlachcic, L. Opalinski, M. Zakrzewska and J. Otlewski, *Int. J. Mol. Sci.*, 2018, **19**, 16.
- 51 M. A. Krzyscik, L. Opalinski and J. Otlewski, *Mol. Pharmaceutics*, 2019, **16**, 3588–3599.
- 52 A. Pryma, K. Matinkhoo, A. A. Wong and D. M. Perrin, *Chem. Sci.*, 2020, **11**(43), 11927–11935.
- 53 P. B. Lawrence and J. L. Price, *Curr. Opin. Chem. Biol.*, 2016, **34**, 88–94.
- 54 A. Maruani, M. E. Smith, E. Miranda, K. A. Chester, V. Chudasama and S. Caddick, *Nat. Commun.*, 2015, **6**, 1–9.
- 55 L. R. Jones, E. A. Goun, R. Shinde, J. B. Rothbard, C. H. Contag and P. A. Wender, *J. Am. Chem. Soc.*, 2006, **128**, 6526–6527.
- 56 M. H. Lee, Z. Yang, C. W. Lim, Y. H. Lee, S. Dongbang, C. Kang and J. S. Kim, *Chem. Rev.*, 2013, **113**, 5071–5109.
- 57 C. Muniesa, V. Vicente, M. Quesada, S. Saez-Atienzar, J. R. Blesa, I. Abasolo, Y. Fernandez and P. Botella, *RSC Adv.*, 2013, **3**, 15121–15131.
- 58 P. A. Wender, E. A. Goun, L. R. Jones, T. H. Pillow, J. B. Rothbard, R. Shinde and C. H. Contag, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 10340–10345.
- 59 W. Zhang, J. J. Song, B. Z. Zhang, L. W. Liu, K. R. Wang and R. Wang, *Bioconjugate Chem.*, 2011, **22**, 1410–1415.
- 60 M. Sengee, J. J. Eksteen, S. L. Nergard, T. Vasskog and L. K. Sydnes, *Bioconjugate Chem.*, 2019, **30**, 1489–1499.
- 61 I. R. Vlahov, F. You, H. K. R. Santhapuram, Y. Wang, J. F. Vaughn, S. J. Hahn, P. J. Kleindl, M. J. Fan and C. P. Leamon, *Bioorg. Med. Chem. Lett.*, 2011, **21**, 1202–1205.



- 62 D. L. Zhang, T. H. Pillow, Y. Ma, J. dela Cruz-Chuh, K. R. Kozak, J. D. Sadowsky, G. D. L. Phillips, J. Guo, M. Darwish, P. Fan, J. T. Chen, C. R. He, T. Wang, H. Yao, Z. J. Xu, J. H. Chen, J. Wai, Z. H. Pei, C. Hop, S. C. Khojasteh and P. S. Dragovich, *ACS Med. Chem. Lett.*, 2016, **7**, 988–993.
- 63 A. K. Jain, M. G. Gund, D. C. Desai, N. Borhade, S. P. Senthilkumar, M. Dhiman, N. K. Mangu, S. V. Mali, N. P. Dubash, S. Halder and A. Satyam, *Bioorg. Chem.*, 2013, **49**, 40–48.
- 64 S. A. Kularatne, C. Venkatesh, H. K. R. Santhapuram, K. Wang, B. Vaitilingam, W. A. Henne and P. S. Low, *J. Med. Chem.*, 2010, **53**, 7767–7777.
- 65 J. Lu, F. Jiang, A. P. Lu and G. Zhang, *Int. J. Mol. Sci.*, 2016, **17**, 22.
- 66 J. D. Bargh, A. Isidro-Llobet, J. S. Parker and D. R. Spring, *Chem. Soc. Rev.*, 2019, **48**, 4361–4374.
- 67 S. O. Doronina, B. A. Mendelsohn, T. D. Bovee, C. G. Cervený, S. C. Alley, D. L. Meyer, E. Oflazoglu, B. E. Toki, R. J. Sanderson and R. F. Zabinski, *Bioconjugate Chem.*, 2006, **17**, 114–124.
- 68 I. E. Valverde, A. F. Delmas and V. Aucagne, *Tetrahedron*, 2009, **65**, 7597–7602.
- 69 V. Aucagne and D. A. Leigh, *Org. Lett.*, 2006, **8**, 4505–4507.
- 70 O. D. Montagnat, G. Lessene and A. B. Hughes, *Tetrahedron Lett.*, 2006, **47**, 6971–6974.
- 71 H. C. Kolb, M. G. Finn and K. B. Sharpless, *Angew. Chem., Int. Ed.*, 2001, **40**, 2004–2021.
- 72 V. V. Rostovtsev, L. G. Green, V. V. Fokin and K. B. Sharpless, *Angew. Chem., Int. Ed.*, 2002, **41**, 2596–2599.
- 73 H. C. Kolb and K. B. Sharpless, *Drug Discovery Today*, 2003, **8**, 1128–1137.
- 74 Q. Wang, T. R. Chan, R. Hilgraf, V. V. Fokin, K. B. Sharpless and M. G. Finn, *J. Am. Chem. Soc.*, 2003, **125**, 3192–3193.
- 75 A. Pryma, S. Gunasekera, J. Lewin and D. M. Perrin, *Bioconjugate Chem.*, 2020, **31**, 2685–2690.
- 76 B. Q. Wei, J. Gunzner-Toste, H. Yao, T. Wang, J. Wang, Z. J. Xu, J. H. Chen, J. Wai, J. Nonomiya, S. P. Tsai, J. Chuh, K. R. Kozak, Y. C. Liu, S. F. Yu, J. Lau, G. M. Li, G. D. Phillips, D. Leipold, A. Kamath, D. A. Su, K. Y. Xu, C. Eigenbrot, S. Steinbacher, R. Ohri, H. Raab, L. R. Staben, G. L. Zhao, J. A. Flygare, T. H. Pillow, V. Verma, L. A. Masterson, P. W. Howard and B. Safina, *J. Med. Chem.*, 2018, **61**, 989–1000.
- 77 U. Bermbach and H. Faulstich, *Biochemistry*, 1990, **29**, 6839–6845.
- 78 V. Almendro, A. Marusyk and K. Polyak, in *Annual Review of Pathology: Mechanisms of Disease, Vol 8*, ed. A. K. Abbas, S. J. Galli and P. M. Howley, Annual Reviews, Palo Alto, 2013, vol. 8, pp. 277–302.
- 79 S. J. Altschuler and L. F. Wu, *Cell*, 2010, **141**, 559–563.
- 80 M. K. Jolly, P. Kulkarni, K. Weninger, J. Orban and H. Levine, *Front. Oncol.*, 2018, **8**, 50.
- 81 A. Zimmer, S. Amar-Farkash, T. Danon and U. Alon, *BMC Syst. Biol.*, 2017, **11**, 33.
- 82 M. Kaern, T. C. Elston, W. J. Blake and J. J. Collins, *Nat. Rev. Genetics*, 2005, **6**, 451–464.
- 83 Z. Inde and S. J. Dixon, *Crit. Rev. Biochem. Mol. Biol.*, 2018, **53**, 99–114.
- 84 K. Letschert, H. Faulstich, D. Keller and D. Keppler, *Toxicol. Sci.*, 2006, **91**, 140–149.
- 85 H. Faulstich, H. Trischmann, T. Wieland and E. Wulf, *Biochemistry*, 1981, **20**, 6498–6504.

